All Oncology News

Edward B. Garon, MD, MS, takes stock of the non–small cell lung cancer field in light of recent updates from clinical trials.

First-line lenvatinib plus pembrolizumab demonstrated antitumor activity across various histologic subtypes in advanced or recurrent endometrial cancer.

Durvalumab plus chemotherapy, followed by durvalumab maintenance with or without olaparib, improved responses in advanced endometrial cancer.

The FDA has approved adagrasib plus cetuximab for patients with KRAS G12C–mutant locally advanced or metastatic colorectal cancer.

Patients with leptomeningeal metastasis from HER2-positive breast cancer experienced clinical benefit with tucatinib plus trastuzumab and capecitabine.

MB-106 showcased a favorable safety profile and elicited responses in heavily pretreated patients with refractory Waldenström macroglobulinemia.

The EMA has validated an extension application for the subcutaneous formulation of nivolumab in adult patients with solid tumor indications.

Mirvetuximab soravtansine generated PFS, OS, and ORR improvements in patients with ovarian cancer who required dose modifications in the MIRASOL trial.

Three Huntsman Cancer Institute researchers have recently been recognized for their work as outstanding faculty members at the University of Utah.

Komal Jhaveri, MD, FACP, highlights the novel PI3Kα inhibitor RLY-2608 and discusses the details of the first-in-human trial of the agent.

Durvalumab/chemotherapy/bevacizumab, then durvalumab/bevacizumab/olaparib maintenance, sustained a PFS benefit in BRCA-unmutated advanced ovarian cancer.

ROCSAN step 1 did not meet its primary end point of 16-week response rate with niraparib or dostarlimab/niraparib in endometrial/ovarian carcinosarcoma.

Vibostolimab plus pembrolizumab was not superior to pembrolizumab monotherapy in pretreated PD-L1–positive advanced cervical cancer.

XB2001 plus chemotherapy improved safety and was tied to a trend toward improved overall survival in pretreated advanced pancreatic cancer.

Florida Cancer Specialists & Research Institute spotlights a study uncovering a new testing method to determine personalized care options in NSCLC.

Tafasitamab plus lenalidomide has been granted priority review in China for transplant-ineligible, relapsed/refractory diffuse large B-cell lymphoma.

Capivasertib/fulvestrant was approved in the EU for pretreated, ER-positive, HER2‑negative advanced cancer with 1 or more PIK3CA, AKT1, or PTEN alterations.

DESTINY-Breast03 and DESTINY-Breast06 showed that T-DXd is a beneficial treatment approach in HER2-positive, -low, and -ultralow metastatic breast cancer.

Liso-cel demonstrated clinically meaningful activity regardless of the number of previous lines of systemic therapy or response to prior BTK inhibitors in MCL.

Frontline zanubrutinib/rituximab induction followed by short-course chemotherapy yielded efficacy in mantle cell lymphoma.

Minoo Battiwalla, MD, discusses the role of bispecific antibodies as an alternative to CAR T-cell therapies in NHL, treatment strategies for aggressive follicular lymphomas, and more.

Emavusertib monotherapy was tolerable and produced responses in patients with FLT3-mutant relapsed/refractory acute myeloid leukemia.

Aditya Bardia, MD, MPH, FASCO, discusses the evolving role of T-DXd for patients with HER2-positive advanced breast cancer.

Dana-Farber Cancer Institute investigators have found that people experience discrimination in different ways and in various realms of cancer care.

The FDA placed partial clinical holds on trials evaluating azenosertib in advanced solid tumors, including ovarian cancer and uterine serous carcinoma.

Golidocitinib has received approval from China’s NMPA for relapsed/refractory peripheral T-cell lymphoma.

Lauren E. Nye, MD, highlights reasons to look beyond CDK4/6 inhibitors when determining treatments for patients with hormone receptor–positive advanced breast cancer and more.

Sid Devarakonda, MD, details how new treatment strategies in the neoadjuvant and adjuvant settings are being implemented in the non–small cell lung cancer arena.

TP53 mutations have an adverse prognostic role in CLL, regardless of 17p deletion status, in the context of chemoimmunotherapy and targeted agents.

Eric Vallieres, MD, FRCSC, discussed recent advancements in surgical oncology regarding the treatment of patients with non–small cell lung cancer (NSCLC)